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Abstract
The cell intrinsic innate immune responses provide a first line of defense against viral infection, and often function by
targeting cellular pathways usurped by the virus during infection. In particular, many viruses manipulate cellular lipids to
form complex structures required for viral replication, many of which are dependent on de novo fatty acid synthesis. We
found that the energy regulator AMPK, which potently inhibits fatty acid synthesis, restricts infection of the Bunyavirus,
Rift Valley Fever Virus (RVFV), an important re-emerging arthropod-borne human pathogen for which there are no
effective vaccines or therapeutics. We show restriction of RVFV both by AMPK and its upstream activator LKB1, indicating
an antiviral role for this signaling pathway. Furthermore, we found that AMPK is activated during RVFV infection, leading
to the phosphorylation and inhibition of acetyl-CoA carboxylase, the first rate-limiting enzyme in fatty acid synthesis.
Activating AMPK pharmacologically both restricted infection and reduced lipid levels. This restriction could be bypassed
by treatment with the fatty acid palmitate, demonstrating that AMPK restricts RVFV infection through its inhibition of
fatty acid biosynthesis. Lastly, we found that this pathway plays a broad role in antiviral defense since additional viruses
from disparate families were also restricted by AMPK and LKB1. Therefore, AMPK is an important component of the cell
intrinsic immune response that restricts infection through a novel mechanism involving the inhibition of fatty acid
metabolism.
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Introduction
Emerging and re-emerging arthropod-borne viral pathogens
have lead to significant world-wide morbidity and mortality in
humans and domestic animals, and are of medical and agricultural
concern. Bunyaviruses are an important group of insect-borne
RNA viruses that include disease causing members such as Sin
Nombre, Hantavirus, Crimean-Congo hemorrhagic fever virus,
and Rift Valley Fever Virus (RVFV). RVFV is a mosquito borne
Category A agent initially endemic to sub-Saharan Africa.
However, outbreaks of RVFV have recently occurred in Egypt
and the Arabian Peninsula, indicating the potential of this virus to
spread to new geographical areas [1]. RVFV has particular
importance as an agricultural pathogen, where infection of
livestock can lead to significant morbidity and mortality among
young animals, and cause catastrophic abortion rates [1]. Most
humans infected with RVFV develop self-limited febrile illness,
although approximately 1–3% die from the disease due to
hemorrhagic symptoms [2–5]. No effective vaccines or antiviral
therapies have yet been developed against RVFV.
All viruses undergo sequential steps to complete their replication
cycles. Bunyaviruses and other RNA viruses compartmentalize
their RNA replication machinery on cellular membranes. An
essential feature of these infections is the ability of viruses to
rearrange and proliferate internal cellular membranes into distinct
structures compartmentalizing the viral replication complex and
supporting viral genome replication [6]. Depending on the virus,
these membrane modifications can be derived from distinct
cellular sources, including ER, Golgi, endosomal, and mitochon-
drial membranes, and may have complex biogenesis pathways
derived from multiple intracellular origins [7–14]. Bunyamwera
virus, a member of the Bunyavirus family related to RVFV,
induces the formation of a new Golgi membrane-derived tubular
structure with a globular head that harbors the viral replication
complex [14,15]. Disrupting the formation of this structure is
associated with decreased levels of virus replication [15]. While
different families of viruses use membranes derived from different
cellular sources, and create membranous structures with distinct
morphologies, there are some similarities in these structures,
suggesting that commonalities exist in the mechanisms by which
disparate viruses depend upon lipid metabolism or trafficking [16].
One clear point of overlap includes a requirement for cellular lipid
biogenesis pathways and the generation of newly synthesized lipids
[6]. Furthermore, enveloped viruses, which include Bunyaviruses,
require incorporation of cellular membranes into their lipid
envelopes during virus assembly, in a process that may also involve
lipid modifications [17].
AMP-activated Kinase (AMPK) is a heterotrimeric complex
that is the core energy sensor of the cells [18]. Thus AMPK
activity is important for survival during periods of stress, and also
has implications in type II diabetes, obesity, metabolic syndrome,
longevity, and cancer [19–25]. The AMPK complex consists of a
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[26]. Activation is triggered through binding of AMP or ADP to
the Bateman domains of the gamma subunit, leading to increased
phosphorylation of the threonine 172 on the alpha subunit by
inducing allosteric activation and inhibiting dephosphorylation
[27–30]. The canonical upstream activator that catalyzes this
phosphorylation event is the constitutively active tumor suppressor
LKB1, but additional activators such as CaMKKb have been
identified [31–35]. Under conditions of energetic stress, AMPK
signals the cell to stop anabolic pathways and activate a catabolic
state by inducing oxidative pathways that generate energy while
inhibiting synthesis and growth pathways, thereby returning the
cell to a state of energy homeostasis [26]. To achieve this
regulation, AMPK targets a number of downstream pathways
including those involved in lipid metabolism.
As a potent regulator of lipid metabolism, AMPK activity
inhibits both sterol and fatty acid synthesis, while promoting fatty
acid degradation [18]. AMPK directly phosphorylates acetyl-CoA
carboxylase (ACC) and HMG-CoA Reductase (HMGCR),
thereby inactivating these rate limiting enzymes in the metabolism
of fatty acids and sterols respectively [36,37]. In particular, ACC
catalyzes the irreversible conversion of acetyl-CoA to malonyl-
CoA, a key metabolite that plays multiple roles in fatty acid
metabolism. First, malonyl-CoA is the substrate for fatty acid
biogenesis, which drives de novo production of the fatty acid
palmitate [38]. Second, malonyl-CoA is a co-substrate for chain
lengthening of endogenously synthesized and dietary-derived
essential fatty acids into higher polyunsaturated fatty acids [39].
Third, malonyl-CoA binding inhibits carnitine palmitoyltransfer-
ase I (CPT-1), an essential factor in the transport of fatty acids to
the mitochondria for beta oxidation [38]. Thus malonyl-CoA
production by ACC promotes fatty acid synthesis, while inhibiting
fatty acid oxidation. Mammalian systems encode two non-
redundant ACC isoforms, ACC1 and ACC2, which are both
inactivated by AMPK-mediated phosphorylation. Studies suggest
that malonyl-CoA produced by ACC2 is involved in fatty acid
oxidation, while ACC1 contributes to fatty acid biogenesis [18].
Therefore, activation of AMPK through stress or low energy
conditions induces fatty acid oxidation through ACC2, while
inhibiting fatty acid synthesis through ACC1, with a net result of
lipid breakdown.
We found that AMPK is potently antiviral against RVFV, and
this restriction is dependent on the upstream activator LKB1.
Furthermore, pharmacological activation of AMPK inhibited viral
infection. AMPK was activated by RVFV infection, and in
particular we observed striking changes in ACC activity dependent
on AMPK, leading us to discover that AMPK is antiviral through
its role in fatty acid metabolism. Cells lacking AMPK had
increased global lipid levels, while pharmacological activation of
AMPK led to decreased cellular lipids, consistent with AMPK
control of lipid availability as a restriction point for viral
replication. Importantly, we could bypass the antiviral effects of
AMPK by feeding cells palmitate, the first fatty acid produced
downstream of ACC. Since palmitate treatment restored RVFV
infection, we demonstrate that AMPK specifically restricts
infection through its role in inhibiting fatty acid biosynthesis.
Since many viruses are dependent upon fatty acid biosynthesis for
their replication, we tested whether AMPK restricted additional
RNA viruses. We found that indeed, AMPK has antiviral activity
against multiple arboviruses from disparate families including: the
Flavivirus Kunjin virus, the Togavirus Sindbis virus, and the
Rhabdovirus Vesicular stomatitis virus. Taken together, our data
suggest that AMPK activation is broadly anti-viral, and may
provide a novel antiviral therapeutic target.
Results
AMPK Restricts RVFV Infection
We previously reported that AMPK was required for efficient
vaccinia infection through its role in macropinocytosis [40]. This
led us to investigate the role of AMPK in other virus infections; we
were particularly interested in RVFV as it is a virus that is
medically important, but little is known about the mechanisms by
which it establishes a productive infection. For our studies we used
the lab adapted strain MP12 that has 11 amino acid differences
from the wild type strain, since the wild type strain must be used in
high containment facilities [41]. In order to test the role of AMPK
in RVFV infection, we took advantage of mouse embryonic
fibroblasts (MEF) that are genetically altered and null for both of
the catalytic a subunits, AMPKa1 and AMPKa2 (AMPKa1/
AMPKa2
2/2) [42–44]. We challenged either the AMPKa1/
AMPKa2
2/2 MEFs or their sibling control wild type MEFs with
RVFV and measured infection by plaque assay (Figure 1A). We
found an increase in titer from 5610
5 pfu/ml to 3610
6 pfu/ml,
indicating a 6-fold increase in the number of plaques formed in
AMPKa1/AMPKa2
2/2 MEFscompared to wild type(Figure 1B),
concomitant with a 4-fold increase in average plaque area in
AMPKa1/AMPKa2
2/2 MEFs (Figure 1C). Moreover, RVFV
infection was also increased in AMPKa1/AMPKa2
2/2 MEFs as
measured by an immunofluorescence assay that detects production
of the RVFV N protein produced during viral replication
(Figure 1D, quantified in Figure 1E), indicating that RVFV is
able to infect and spread more efficiently in the absence of AMPK.
Consistent with a role for AMPK both in early events during viral
replication and in spread as measured by plaque assay Figure 1A),
we observed an increase in viral infection at early time points
before virus spread, as well as increased spread in cells lacking
AMPK by monitoring the production of RVFV N protein over
time by microscopy (Figure S1A–B).
This increased spread, indicated by the increase in plaque size
(Figure 1C), as well as the immunofluorescence assay (Figure S1A–
B), could result from increased production of infectious virus or
increased infectivity of the virions produced in cells lacking
Author Summary
RNA viruses represent an important worldwide source of
infection and disease in both humans and animals. While
individual viruses have unique characteristics, some stages
of infection are conserved and must be completed in order
to successfully infect and grow. Viruses must undergo
genome replication, protein synthesis, and assembly of
new virus particles. In particular, numerous RNA viruses
manipulate cellular membranes to create new complex
structures required for viral replication in a process that is
often dependent on fatty acid biosynthesis. This is a
process that is tightly regulated by the energy sensor
AMPK. We have found that energy-mediated activation of
AMPK restricts infection of the Bunyavirus Rift Valley fever
virus by decreasing levels of fatty acid synthesis. Further-
more, several additional RNA viruses from disparate
families that share this dependence of membrane modi-
fication and fatty acid synthesis are also restricted by
AMPK. Thus AMPK likely represents a novel component of
the cell intrinsic immune response to RNA viruses, and may
be a good target for the development of antiviral
therapeutics against a range of medically important
viruses.
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wild type and AMPKa1/AMPKa2
2/2 MEFs over time in a one-
step growth curve. Medium from infected cells was collected at
various times after infection, and virus was tittered on wild type
BHK cells. Little virus (less than 1610
4 pfu/ml) was detected at 2–
4 hpi, indicating that input virus was not detected in this assay
(Figure 1F). Virus release began at 8 hpi, where we already
observed an 8-fold increase in titer in the AMPK deficient MEFs
(1.6610
5 pfu/ml versus 1.3610
6) (Figure 1F). This increase in titer
was also observed at 12 hpi. Therefore, the increase in RVFV
spread is likely due to increased virus production in AMPKa1/
AMPKa2
2/2 MEFs.
AMPK Activation Restricts RVFV
AMPK is activated through phosphorylation of a threonine
residue on the catalytic alpha subunit [45]. Since AMPK
deficiency increased RVFV infection, we hypothesized that
AMPK activation would inhibit infection. Therefore, we tested
whether RVFV was sensitive to pharmacological treatments that
activate AMPK. First, we tested drugs that activate AMPK by
reducing the levels of cellular energy using an independent cell
line, the human osteosarcoma cell line (U2OS). We tested the
glucose analog 2-deoxyglucose (2DG), and the ATP synthase
inhibitor oligomycin, and found that both treatments significantly
decreased infection by RVFV compared to vehicle controls
(Figure 2A). In contrast, the AMPK inhibitor Compound C
significantly, albeit modestly, increased RVFV infection (Figure
S2A). Since 2DG and oligomycin activate AMPK indirectly by
reducing cellular energy levels, and thus likely have other effects
that may also contribute to viral infection, we tested whether these
treatments affected vaccinia virus infection, which is not restricted
by AMPK, but rather requires AMPK, independent of the energy
sensing pathway for efficient viral infection [40]. Vaccinia virus
infection was not affected by these treatments (Figure 2B),
indicating that the compound-treated cells remain healthy enough
to support viral infection, and the reduced infection levels were
specific to RVFV. Moreover, we found that none of these drug
treatments reduced cell number by greater that 20%, and
therefore were not cytotoxic (Figure S2B).
Next, we took advantage of a recently developed thienopyr-
idone compound A769662 that activates AMPK directly,
independently of the energy status of the cell [46,47]. This drug
mimics both allosteric activation of AMPK and inhibition of
dephosphorylation without affecting binding of AMP to the
gamma subunit [48]. We found that RVFV infection of U2OS
cells was significantly reduced in the presence of this compound
(Figure 2C), and that both 2DG and A769662 inhibit RVFV in a
dose-dependent manner (Figure S3A–B), indicating that AMPK
activation restricts RVFV infection independently of the pleiotro-
pic effects of reduced cellular energy levels. Moreover, we also
found that the AMPK activating drugs 2DG and A769662
significantly inhibit RVFV infection in MEFs (Figure 2D). To
determine if the effects of these drugs was specific for AMPK we
treated AMPKa1/AMPKa2
2/2 MEFs with the direct AMPK
activator A769662. Treatment with this drug inhibited RVFV less
than 2 fold in AMPKa1/AMPKa2
2/2 MEFs and was not
significant, whereas infection was inhibited greater than 5-fold in
the wild type cells (Figure S4A) with no toxicity in either cell type
(Figure S4B), indicating that the major action of this drug was
through AMPK as previously published [46,47]. Taken together,
these studies suggest that AMPK activation has antiviral activity
against RVFV in multiple cell types.
Figure 1. AMPK restricts RVFV infection. A. Plaque assays were performed on wild type (WT) and AMPKa1/AMPKa2
2/2 MEFs. Representative
data from triplicate experiments is shown. B. Quantification of plaques from A. presented as the normalized mean6SD relative to the number of wild
type plaques from three experiments. C. The diameter of 30 representative plaques in each duplicate well from A. was used to calculate the average
plaque area, displayed as the normalized mean+SD in triplicate experiments. D. WT or AMPKa1/AMPKa2
2/2 MEFs were infected with serial dilutions
of RVFV, incubated for 16 hours, and processed for immunofluorescence. (RVFV-N, green; nuclei, blue). E. Quantification of D. presented as percent
of infected cells. A representative of three experiments is shown. F. One-step growth curve of RVFV in WT or AMPKa1/AMPKa2
2/2 MEFs. RVFV grown
in WT or AMPKa1/AMPKa2
2/2 MEFs for 4, 8, or 12 hours was tittered on BHK cells and is presented as the normalized mean of triplicate experiments
6SD. * indicates p,0.05.
doi:10.1371/journal.ppat.1002661.g001
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Since pharmacological activation of AMPK restricted RVFV
infection, we were interested in investigating which pathway
upstream of AMPK was responsible for this restriction. The classic
activator of AMPK is the tumor suppressor LKB1, which
phosphorylates AMPK in response to a variety of stimuli that
cause a reduction in cellular energy levels, such as glucose
starvation or hypoxia [26]. In order to determine if LKB1
signaling was important for AMPK-mediated RVFV restriction,
we tested whether LKB1 also restricted RVFV. We challenged
MEFs that are null for LKB1 and complemented with either
vector alone (LKB1
2/2; Vec), or an LKB1 cDNA (LKB1
2/2;
LKB1) [40] and found increased RVFV infection in MEFs lacking
LKB1 by plaque assay (Figure 3A). Quantification revealed a 2-
fold increase in the number of plaques (increase in average virus
titer from 7.8610
5 to 1.5610
6 pfu/ml in LKB1 null MEFs)
(Figure 3B) and a 5-fold increase in plaque area in LKB1
2/2; Vec
MEFs compared to MEFs complemented with LKB1 (Figure 3C).
Moreover, we observed increased infection in the LKB1
2/2; Vec
MEFs compared to those complemented with LKB1 by
immunofluorescence (Figure 3D, quantified in 3E). Finally, we
measured RVFV infection over time in cells lacking LKB1 and
found increased infection in the absence of LKB1 at early and late
times after infection, indicating increased initial infection as well as
spread (Figure 3F). Since AMPK activation downstream of LKB1
is dependent on a decrease in cellular energy, we measured
cellular ATP levels during RVFV infection using a luciferase assay.
While 2DG significantly reduced cellular ATP levels, neither
A769662 nor RVFV had any impact on ATP levels as measured
by this assay (Figure S5). While infection with RVFV did not
induce global changes in cellular ATP, this does not rule out
localized changes in cellular energy that could influence AMPK.
In addition to LKB1 other upstream activators of AMPK have
been identified. Notably, calcium-calmodulin kinase kinase
(CaMKK) has been shown to activate AMPK in response to an
increase in intercellular calcium [33,34,49]. Since LKB1 did not
restrict RVFV as strongly as AMPK did (Figure 3), we investigated
if other upstream activators, such as CaMKK could also
contribute to RVFV restriction. To this end, we treated U2OS
cells with the CaMKK inhibitor STO609 prior to infection, and
found no increase in RVFV infection in response to this drug,
although at very high concentrations there was a decrease in
infection (Figure S3C). This decrease was likely due to additional
kinases that are inhibited at these concentrations [50]. This finding
is consistent with previous reports that changes in intercellular
calcium levels are not induced by RVFV infection [51]. We next
investigated if LKB1 and CaMKK function redundantly to restrict
RVFV infection. We tested whether simultaneously inhibiting
both LKB1 and CaMKK would lead to a greater increase in
RVFV infection than LKB1 deficiency alone. To this end, prior to
infection, we treated LKB1 null MEFs or those complemented
with LKB1 with STO609 and monitored RVFV infection.
Consistent with our previous findings, we observed a 3-fold
increase in the percentage of infected cells in LKB1 null cells
compared to those complemented with LKB1; however pretreat-
ment with STO609 had no effect on infection level in either cell
type (Figure 3G). In contrast, and as expected, we found that
pretreatment with the AMPK activating compound A769662
significantly inhibited RVFV in both LKB1 null and comple-
mented MEFs (Figure 3G). Taken together, these data suggest that
Figure 2. AMPK activation restricts RVFV. A–B. U2OS cells were pretreated with 10 mM 2DG, 10 mM oligomycin or PBS (untreated) for 1 hour
and infected with serial dilutions of RVFV (A) for 10 hours or vaccinia virus (B) for 8 hours and processed for immunofluorescence. Data are displayed
as the average percent infection relative to the highest concentration of virus in the untreated control 6 SD from triplicate experiments. C–D. U2OS
cells (C) or MEFs (D) were pretreated with 12 mM 2DG, 100 mM A769662, or PBS for 1 hour and infected with RVFV (MOI 1) for 10 hours. Infection was
measured by immunofluorescence. Data are displayed as the normalized percent infection relative to the untreated control 6SD in triplicate
experiments; * indicates p,0.05.
doi:10.1371/journal.ppat.1002661.g002
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mediated restriction of RVFV.
AMPK Restricts RVFV RNA Replication
To dissect the mechanism by which AMPK restricts RVFV
infection, we first determined which early step in the viral
replication cycle is restricted by AMPK. We observed decreased
protein production, as measured by immunofluorescence
(Figure 1D–E and Figure S1) in addition to decreased production
of infectious progeny virus (Figure 1F) in the presence of AMPK.
This suggests that AMPK may inhibit a step in the viral replication
cycle at, or prior to, protein production. To determine if viral
RNA replication was affected by AMPK, we monitored both viral
genomic RNA replication and viral mRNA production in the
presence or absence of AMPK. We found an increase in both viral
mRNA (N) and genomic RNA (S segment) in AMPK deficient
MEFs both early in infection and upon virus spread (Figure 4A–
C). At 4 hpi, a time point prior to RVFV release, we observed a 3-
fold increase in viral mRNA production in AMPK deficient MEFs
compared to wild type, which continued to increase over time
(Figure 4A–B). Likewise, genomic RNA production was increased
prior to virus release and spread (Figure 4A and C). These data
suggest that the increased N protein production observed by
immunofluorescence at early time points (Figure S1A) may be due
to increased N mRNA production.
Next, we investigated whether entry, a step upstream of RNA
replication, was inhibited by AMPK. First, we tested whether
RVFV binding was more efficient in the absence of AMPK. To
this end, MEFs were pre-bound with RVFV for an hour at 4uC,
unbound virus was removed and RVFV binding was measured by
Figure 3. LKB1 restricts RVFV infection. A. RVFV was plaqued on LKB12/2;LKB1 and LKB12/2;Vec MEFs. Representative data from triplicate
experiments is shown. B. Quantification of plaques from A. presented as the normalized mean6SD of wild type plaques from three experiments. C.
The diameter of 30 representative plaques each of three experiments was used to calculate the average plaque area, which is displayed as the
normalized mean6SD in triplicate experiments. D. LKB12/2;LKB1 or LKB12/2;Vec MEFs were infected with serial dilutions of RVFV, incubated for
16 hours, and processed for immunofluorescence. (RVFV-N green; nuclei blue). A representative of triplicate experiments is shown. E. Quantification
of D. presented as RVFV percent infection in LKB12/2;LKB1 and LKB12/2;Vec MEFs. A representative of triplicate experiments is shown. F. Time
course of RVFV infection in LKB12/2;LKB1 and LKB12/2;Vec MEFs. Cells were infected with RVFV (MOI 1), and fixed at indicated hours post infection.
A representative of triplicate experiments is shown. G. LKB12/2;LKB1 or LKB12/2;Vec MEFs were pretreated with 100 mM A769662 or 10 mg/ml
STO609 for 1 hour prior to infection with RVFV (MOI 1) for 10 hours and processed for immunofluorescence. Data are displayed as the average
percent infection relative to the LKB12/2;LKB1 untreated control 6 SD from triplicate experiments. * indicates p,0.05.
doi:10.1371/journal.ppat.1002661.g003
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virions. We observed no difference in virus binding in wild type or
AMPK deficient cells (Figure 4D). Moreover, the majority of virus
was removed by trypsin treatment in both wild type and AMPK
deficient MEFs, indicating these virions had bound to the cell
surface, but not entered (Figure 4D).
Since AMPK did not impede virus binding, we next performed
a time of addition assay to test whether AMPK-activating drugs
restricted entry. Since Bunyaviruses such as RVFV enter cells
through a pH-dependent route of endocytosis [51–53], we used
the lysosomotropic agent ammonium chloride, which raises the
pH of lysosomal compartments, to define the timing of virus entry.
Ammonium chloride inhibited infection strongly (to 20% of the
4 hpi addition) when added 1 hour prior to infection or with
infection (t=0); however, by 1 hpi, more than 70% of infection
had returned, indicating that the majority of RVFV had entered
by this time point (Figure 4E). Thus we compared each treatment
to the post entry level of RVFV infection (ammonium chloride
added at 4 hpi). AMPK activating drugs 2DG, and A769662
significantly inhibited infection when added at post entry stages
(Figure 4E); however, since one of the AMPK activating drugs,
A769662, had a significantly greater impact on RVFV when
added prior to or with infection, we cannot rule out that AMPK
also inhibits RVFV entry. Taken together these data suggest that
AMPK restricts RVFV during initial stages of replication post
entry, likely at the step of RNA replication. This reduction in viral
RNA and protein production likely leads to a reduction in release
of infectious virus and spread observed at later stages of infection.
The Antiviral Effects of AMPK Are Independent of Type I
Interferon
The classical cell-mediated response to viral infection is the type
I interferon system [54,55]. Therefore, we investigated whether
AMPK impacts the expression of interferon beta (IFNb) or its
downstream effector 29-59-oligoadenylate synthetase 1 (OAS1) by
qRT-PCR. We found that RVFV infection induced both IFNb
and OAS1 in both wild type and AMPK deficient cells although
the basal levels and induction of these genes were higher in cells
lacking AMPK (Figure S6A–B). This result was opposite to what
would have been predicted, if IFNb induction was responsible for
the antiviral phenotype. In addition, we tested whether IFNb
treatment induced AMPK or ACC phosphorylation and found
that it did not (Figure S6C, quantified in D). Altogether, these data
indicate that AMPK has antiviral activity independent of the
classical type I IFN response.
Acetyl-CoA Carboxylase Activity Is Tightly Regulated by
AMPK during RVFV Infection
Since AMPK activation has antiviral activity against RVFV, we
examined whether AMPK is activated by RVFV infection. To this
end, we measured AMPK phosphorylation at Thr172 by
immunoblot. AMPK phosphorylation was increased at 4 and
8 hours after infection compared to uninfected controls (Figure 5A,
quantified in Figure S7A), indicating that RVFV infection induced
AMPK activation. Furthermore, we found that UV-irradiated
virus, incapable of replication (Figure S8), also induced AMPK
phosphorylation at 4 and 8 hours after treatment (Figure 5C),
suggesting that activation was triggered by incoming virus particles
and viral replication was not required. Finally, we confirmed that
LKB1 was required for RVFV-dependent activation of AMPK
(Figure S9).
AMPK regulates several downstream pathways that could be
important for viral infection, in particular protein translation and
lipid synthesis [56]. Thus, we examined the activation status of two
classical downstream effectors of AMPK involved in translation
and lipid biosynthesis which are inactivated by AMPK-mediated
Figure 4. AMPK restricts RVFV RNA replication. A. Northern blot of genomic S segment and N mRNA from RVFV (MOI 1) grown in WT or
AMPKa1/AMPKa2
2/2 MEFs for 4, 8, or 12 hours. A representative of triplicate experiments is shown. B–C. Quantification of RVFV mRNA (B)o r
genomic RNA (C) in WT or AMPKa1/AMPKa2
2/2 MEFs displayed as the normalized fold change from WT 4 hours. A representative of triplicate
experiments is shown. D. RVFV binding assay. RVFV (MOI 10) was bound to WT or AMPKa1/AMPKa2
2/2 MEFs at 4uC for 1 hour, then washed, and
treated with PBS or trypsin to remove bound virus. qRTPCR was performed on isolated RNA to detect RVFV S genome. Data are displayed as the
average DDCT of triplicate experiments normalized to GAPDH control. * indicates p,0.05. E. 2DG (12 mM), A769662 (100 uM) or Ammonium
Chloride (NH4Cl, 12 mM) was added either 1 hour prior to infection with RVFV (MOI 1), with infection, or 1, 2, or 4 hours post infection. After 10 hours
of infection cells were fixed and processed for immunofluorescence. Data are displayed as the average percent infection relative to the post entry
level of infection (NH4Cl added at 4 hpi) 6 SD from triplicate experiments. * indicates p,0.05.
doi:10.1371/journal.ppat.1002661.g004
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regulator of translation elongation, and Acetyl-CoA Carboxylase
(ACC) consists of two enzymes involved in fatty acid metabolism
(ACC1 and ACC2) [38,57]. Both eEF2 and ACC had increased
levels of phosphorylation at 4 and 8 hours after infection with
RVFV compared to uninfected controls, consistent with the
activation status of AMPK (Figure 5A, quantified in Figure S7B–
D). Little difference in total protein levels of AMPK, ACC or eEF2
was observed during infection. Taken together, these data suggest
that RVFV infection leads to increased AMPK signaling.
To explore the mechanism by which AMPK restricts RVFV
replication, we examined the impact of AMPK on translation and
lipid biogenesis, both of which contribute to important steps in
virus infection. In particular, AMPK inhibits translation initiation
by inactivating mTORC1, and translation elongation by inacti-
vating eEF2 [58–60]. Inactivation of mTORC1 by AMPK leads
to decreased translation initiation as well as increased autophagy,
both of which could have anti-viral effects [58]. Since AMPK
activation inhibits mTORC1 activity, we hypothesized that
mTORC1, and thus protein synthesis, would be overactive in
AMPK deficient cells, perhaps allowing for increased viral protein
production and replication. We tested the requirement for
mTORC1 signaling in RVFV infection using the mTORC1
inhibitor Rapamycin, and found no significant difference in
RVFV infection in cells treated with Rapamycin compared to
vehicle controls in either wild type or AMPKa1/AMPKa2
2/2
MEFs (Figure S10A). This finding suggests that the antiviral
activity of AMPK is independent of mTORC1 signaling.
Figure 5. Acetyl-CoA Carboxylase Activity is Tightly Regulated by AMPK during RVFV Infection. A. Phosphorylation of AMPK and
downstream effectors upon RVFV infection. WT MEFs were infected with RVFV (MOI 1) for 4 or 8 hours. Lysates were collected and assayed by
immunoblot for phospho-AMPK, phospho-ACC, and phospho-eEF2. Total protein was assayed for each and Tubulin was measured as a loading
control. Representative blot of triplicate experiments is shown. B. Phosphorylation of AMPK and downstream effectors in WT and AMPKa1/AMPKa2
2/
2 MEFs. Cells were treated with AMPK activators 2DG (12 mM), oligomycin (OM, 10 mM), and A769662 (100 mM) for 4 hours. Lysates were collected
and assayed by immunoblot as above. Representative blot of triplicate experiments shown. C. Phosphorylation of AMPK and ACC upon treatment
with UV-inactivated RVFV. WT MEFs were infected with live or UV-inactivated RVFV (MOI 1) for 4 or 8 hours. Lysates were collected and assayed by
immunoblot as above. Representative blot of triplicate experiments is shown. D. Blocking fatty acid synthesis inhibits RVFV infection. MEFs were
treated with the fatty acid synthase inhibitors Cerulenin (45 pM) and C75 (12.5 mM) or the AMPK activator A769662 (100 mM), infected with RVFV
(MOI 1), and processed for immunofluorescence. Data are displayed as the normalized average percent infection relative to the untreated control 6
SD in triplicate experiments. * indicates p,0.05. E. WT MEFs were treated with 100 mM A769662 for 10 hours and stained for cellular lipids with
BODIPY lipophilic fluorescent dye. (BODIPY, red; nuclei, blue). Representative images from triplicate experiments are shown. F. Quantification of E.
presented as integrated BODIPY intensity per cell relative to untreated control 6 SD in triplicate experiments. * indicates p,0.05. G. WT and
AMPKa1/AMPKa2
2/2 MEFs were grown overnight and stained for cellular lipids with BODIPY lipophilic fluorescent dye. (BODIPY, red; nuclei, blue).
Representative images from triplicate experiments are shown. H. Quantification of G. presented as integrated BODIPY intensity per cell relative to WT
6 SD in triplicate experiments. * indicates p,0.05.
doi:10.1371/journal.ppat.1002661.g005
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which has been shown to have antiviral effects in some models
[61], we tested whether inhibition of autophagy impacted RVFV
infection by plaque assay, and found no significant difference in
MEFs expressing a ATG5 hairpin, which knocks down ATG5,
compared to control MEFs (Figure S10B–C).
Next we investigated whether reduced translation elongation
through eEF2 inactivation could be responsible for AMPK’s
antiviral activity against RVFV (Figure 5A). Since eEF2 is
regulated by multiple upstream pathways in addition to AMPK,
we first determined the sensitivity of eEF2 to AMPK regulation. In
wild type MEFs, treatment with the AMPK activating drugs 2DG,
oligomycin, or A769662 led to increased phosphorylation of
AMPK, as well as downstream effectors eEF2 and ACC
(Figure 5B, quantified in Figure S7E–H), as expected. As a
control, we found that AMPK deficient MEFs did not express
phosphorylated AMPK or total AMPK under any treatment
condition. Interestingly, we observed an increase in phosphory-
lated eEF2 in response to all three drugs in AMPKa1/
AMPKa2
2/2 MEFs (Figure 5B, quantified in Figure S7H). In
contrast, while we observed an increase in ACC phosphorylation
in response to drug treatments in wild type MEFs, phosphorylated
ACC was undetectable in AMPK deficient MEFs both basally and
in response to treatment with AMPK activating compounds
(Figure 5B). These phenotypes were not due to changes in total
protein levels as they remained unchanged under all treatment
conditions; although the AMPK deficient MEFs had a slightly
lower basal level of ACC (Figure 5B). These findings suggest
signaling pathways other than AMPK are important in regulating
eEF2 phosphorylation, while ACC phosphorylation is exquisitely
regulated by AMPK.
Given this observation, we pursued ACC as a potential
regulator of antiviral defense. ACC is the first rate-limiting
enzyme and master regulator of fatty acid metabolism, both by
inhibiting fatty acid biosynthesis and activating fatty acid
catabolism through beta-oxidation [18,38]. Fatty acid biosynthesis
is an important component of viral infection since numerous RNA
viruses, including Bunyaviruses, proliferate cellular membrane
structures for proper formation of the viral replication complex, in
addition to using cellular membranes for their lipid coats
[6,14,15,17]. In order to assess the importance of fatty acid
synthesis in RVFV infection, we tested the ability of RVFV to
replicate within cells pretreated with the fatty acid synthase
inhibitors. Fatty acid synthase is the next enzyme in fatty acid
metabolism, using the product of ACC to generate palmitate, and
thus is required for all fatty acid biosynthesis [62]. We observed a
5-fold decrease in RVFV infection in the presence of fatty acid
synthase inhibitors cerulenin and C75 by immunofluorescence,
similar to the decrease observed in cells pretreated with the AMPK
activator A769662 (Figure 5D), indicating that de novo fatty acid
synthesis is an important step early in RVFV infection.
ACC is the enzyme that converts acetyl-CoA into malonyl-CoA,
a precursor in the synthesis of palmitate, the first product of de novo
fatty acid biosynthesis. Since AMPK activation inhibits de novo
fatty acid synthesis by inactivating ACC, we tested whether altered
levels of AMPK activation or expression affected cellular lipid
levels. To this end, we stained MEFs with the lipophilic BODIPY
fluorescent dye. We found that treatment with the AMPK
activator A769662 led to a decrease in BODIPY staining
compared to untreated MEFs (Figure 5E, quantified in F),
consistent with decreased fatty acid synthesis during AMPK
activation. In contrast, MEFs lacking AMPK had increased
BODIPY staining compared to wild type cells (Figure 5G,
quantified in H). These findings are consistent with previous
reports that AMPK activating drugs, such as A769662 increase
levels of beta-oxidation while decreasing fatty acid synthesis
[46,63,64], and suggest that the absence of AMPK leads to
overproduction of cellular lipids, while AMPK activation globally
reduces cellular lipid levels.
Palmitate Rescues AMPK-Mediated Restriction of RVFV
If AMPK activation restricts RVFV infection by reducing levels
of fatty acid synthesis, exogenous addition of fatty acids should
restore infection. Therefore, we tested whether we could bypass
the requirement for AMPK-regulated fatty acid synthesis by
pretreating cells with palmitate, the first product of fatty acid
biosynthesis. We treated U2OS cells with palmitate overnight, and
then added A769662 1 hour prior to infection with RVFV to
activate AMPK. After 10 hours of infection, cells were fixed and
stained for RVFV to measure percent infection in an immuno-
fluorescence assay that monitors the initial round of infection. In
cells treated with the AMPK activator A769662 alone, we found a
5-fold decrease in RVFV infection, consistent with our previous
findings (Figure 6A, quantified in 6B). However, addition of
palmitate prior to treatment with A769662 was able to restore
infection to levels seen in untreated cells (Figure 6A, quantified in
6B). We observed a 5-fold increase in RVFV infection in cells
treated with A769662 and palmitate compared to those treated
with A769962 alone (Figure 6B), while addition of palmitate alone
had little effect on infection (Figure 6A–B). Since chronic exposure
to high concentrations of palmitate has previously been reported
to inhibit AMPK activation, we confirmed by immunoblot that
AMPK phosphorylation was not inhibited by the concentrations of
palmitate used in our assay (Figure S11). Together, these data
suggest that AMPK restricts RVFV infection primarily through
inhibiting fatty acid biosynthesis.
AMPK Restricts Multiple Arboviruses
A dependence on lipid biosynthesis and virally induced
membrane modifications is not unique to Bunyaviruses; many
RNA viruses require extensive membrane modifications and
proliferations to support their replication complex [6,65].
Therefore, we tested whether AMPK restricts additional arbovi-
ruses. To this end we tested the ability of the Flavivirus Kunjin
virus (KUNV), the Togavirus Sindbis virus (SINV), and the
Rhabdovirus Vesicular stomatitis virus (VSV) to grow in wild type
and AMPKa1/AMPKa2
2/2 MEFs by immunofluorescence.
KUNV (Figure 7A–B), SINV (Figure 7E–F) and VSV (Figure 7I–
J) had increased infections in AMPKa1/AMPKa2
2/2 MEFs
compared to wild type MEFs. Moreover, KUNV (Figure 7C–D),
SINV (Figure 7G–H), and VSV (Figure 7K–L) infections were also
increased in LKB1
2/2; Vec compared to MEFs expressing LKB1,
indicating that both AMPK and its canonical upstream activator
LKB1 restrict additional arboviruses. Moreover, we have found
that KUNV is also sensitive to the AMPK activator A769662, and
can be partially rescued by palmitate addition (Figure S12A–B),
although palmitate treatment itself decreased KUNV infection
(Figure S12C). These data suggest that AMPK may restrict
multiple RNA viruses by limiting fatty acids. Taken together our
data suggest that AMPK is broadly anti-viral across disparate virus
families, and may represent a novel cellular target for anti-viral
therapeutics.
Discussion
Arboviruses represent a group of emerging pathogens of both
medical and agricultural importance for which there are few
therapies. RVFV is a particularly important member of this group
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a Category A pathogen due to its high pathogenesis and potential
for geographical spread. Here, we identified AMPK as a novel
antiviral factor that restricts RVFV infection independent of the
type I IFN system. This restriction is dependent on the canonical
upstream activator LKB1. Furthermore, we found that AMPK is
Figure 6. Addition of palmitate restores RVFV infection in the presence of A769662. A. U2OS cells were pretreated with 100 mM palmitate
overnight and 100 mM A769662 or PBS was added 1 hour prior to infection with RVFV (MOI 1). Cells were incubated for 10 hours, and processed for
immunofluorescence. (RVFV-N, green; nuclei, blue) B. Quantification of A. Data are displayed as the normalized percent infection relative to the
untreated control at MOI 1.256SD in triplicate experiments; * indicates p,0.05 compared to untreated vehicle control.
doi:10.1371/journal.ppat.1002661.g006
Figure 7. Additional arboviruses are restricted by AMPK. WT or AMPKa1/AMPKa2
2/2 MEFs were infected with serial dilutions of KUNV (A),
SINV (E), or VSV (I) and processed for immunofluorescence. (Virus, green; nuclei, blue). Quantifications of the percent infection for KUNV (B), SINV (F)
and VSV (J) are shown as representatives of triplicate experiments. LKB1
2/2;LKB1 and LKB1
2/2;Vec MEFs were infected with serial dilutions of KUNV
(C), SINV (G), and VSV (K) and processed for immunofluorescence. (Virus, green; nuclei, blue). Quantifications of the percent infection are shown for
KUNV (D), SINV (H) and VSV (L) are shown as representatives of triplicate experiments.
doi:10.1371/journal.ppat.1002661.g007
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at the level of RNA replication likely by reducing fatty acid
biosynthesis, an essential process in RVFV infection. We extended
these studies by demonstrating that additional arboviruses, known
to require lipid biosynthesis, were also restricted by this pathway.
Since treatment with drugs that activate AMPK restricted
infection, this could represent a novel therapeutic strategy toward
the control of many RNA viruses.
AMPK is a central regulator of cellular energy that regulates a
number of cellular pathways that could influence viral replication,
including protein and lipid biosynthesis [56]. AMPK activation
inhibits protein translation through two major downstream
pathways. First, AMPK activation inhibits translation initiation
by inhibiting mTORC1 activity. Second, AMPK inhibits
translation elongation through inactivation of eEF2. We explored
these two targets as potentially regulating RVFV infection.
However, we found RVFV was insensitive to treatment with the
mTORC1 inhibitor, Rapamycin, regardless of AMPK status.
Furthermore, eEF2 phosphorylation induced by drugs that alter
the energy status of the cell was not affected in the absence of
AMPK, indicating additional upstream regulators are contributing
to eEF2 activity. Therefore, we explored lipid biosynthesis as a
potential target for AMPK-dependent anti-viral activity.
AMPK controls fatty acid metabolism through ACC, and may
be the only physiologically relevant kinase that controls ACC
activity [18]. This is consistent with our findings that ACC
phosphorylation was exquisitely dependent on AMPK, in contrast
to eEF2, which was phosphorylated during energy depletion even
in the absence of AMPK. ACC is the enzyme responsible for the
conversion of acetyl-CoA to malonyl-CoA [38]. Malonyl-CoA
production impacts lipid metabolism in at least three ways.
Malonyl-CoA is a substrate driving de novo palmitate production,
and is also important in converting simple essential fatty acids into
more complex polyunsaturated fatty acids that can be used to
build triglycerides and other cellular lipids [39]. Finally, malonyl-
CoA inhibits transport of fatty acids to the mitochondria, thus
inhibiting fatty acid oxidation [38]. In addition to its role in fatty
acid metabolism, AMPK is also an important regulator of HMG-
CoA reductase (HMGCR), the rate limiting enzyme in the
synthesis of isoprenoids and sterols, including cholesterol.
Cholesterol is known to contribute to infection of multiple viruses,
and therefore could also be targeted in AMPK-mediated virus
restriction.
Since we found that fatty acid biosynthesis was required for
RVFV infection, and changes to AMPK expression and activation
status led to global changes in cellular lipid levels, we hypothesized
that inhibiting fatty acid synthesis downstream of ACC was
responsible for AMPK-mediated restriction of RVFV. This was
supported by our finding that we could bypass the requirement for
malonyl-CoA production by introducing exogenous palmitate.
Since the addition of palmitate rescued RVFV overcoming the
restriction mediated by AMPK activation (Figure 6), the ability of
AMPK to inhibit fatty acid biosynthesis is likely the most
important determinant of AMPK-mediated RVFV restriction.
Palmitate is a substrate for the biosynthesis of a number of lipid
moieties that could contribute to RVFV infection. Palmitate
undergoes chain elongation and additional modifications in the
ER to produce saturated fatty acids as well as triglycerides,
phospholipids, and cholesterol esters [66,67]. It is also a substrate
for sphingolipid biosynthesis in the Golgi. Sphingolipids become
incorporated into cellular membranes and participate in signaling
events that could contribute to RVFV infection. Finally, palmitate
addition is a form of post-translational modification of some
proteins [68].
There are several stages during the course of RVFV infection
where cellular lipids are utilized. Many RNA viruses induce the
formation of novel membranous structures derived from various
organelles within the cell to support the viral replication complex
[6]. Notably, formation of these structures is often dependent on de
novo fatty acid synthesis [69–72]. While RVFV-induced membrane
alterations have not been well characterized, a related Bunyavirus,
Bunyamwera virus, was reported to induce Golgi-derived tubular
structures with globular heads in association with the viral
replication complex, suggesting that other Bunyaviruses could
likewise induce membrane changes [14,15]. In addition to RNA
replication, enveloped viruses bud from cellular membranes,
thereby incorporating those lipids into the viral particle [17].
RVFV assembly occurs on Golgi membranes, with virus particles
ultimately budding into the Golgi for transport and release at the
plasma membrane [73]. Cellular lipids derived from de novo
palmitate production downstream of ACC could contribute to
each of these steps, although our findings that viral RNA synthesis is
inhibited by AMPK suggests that RNA replication is a key target.
In addition to RVFV, we found that three additional viruses
including the Togavirus SINV, the Flavivirus KUNV, and the
Rhabdovirus VSV are restricted by AMPK and LKB1 (Figure 7).
Importantly, this group includes members of the three major
families of arboviruses that contribute to human disease. Members
of the Togavirus family including Semliki Forest virus and Rubella
virus have been described to induce characteristic modified
endosomal and lysosomal structures termed cytopathic vacuoles
that support the viral replication complex [10,11,74,75]. Further-
more, a number of Flaviviruses have been shown to have
important lipid dependencies. KUNV, a strain of West Nile virus,
has been described as forming two distinct membrane structures
that include double membrane spherical vesicles that are the sites
of viral replication, as well as arrays of convoluted membranes that
are the sites of viral polyprotein processing [76–81]. Moreover,
both fatty acid synthesis and oxidation have been shown to be
essential for another Flavivirus, Dengue virus (DENV). Infection is
characterized by virally-induced increases in cellular fatty acid
synthesis and a redistribution of the enzyme fatty acid synthase to
sites of DENV replication [70]. Free fatty acids are also derived
through autophagosomal processing of triglycerides, and exoge-
nous addition of the fatty acid oleate was able to rescue DENV
infection when autophagy is inhibited [82]. Furthermore,
induction of ER-derived lipid droplet formation is necessary for
DENV particle formation [83]. Therefore DENV and perhaps
many other viruses require complex and unique interactions with
cellular lipid metabolism through both synthesis and degradation
pathways. In addition, Hepatitis C Virus (HCV), a distantly
related Flavivirus, induces formation of a membranous web
derived from intracellular vesicles, whose formation requires fatty
acid synthesis for replication [8,9]. Interestingly, AMPK has been
implicated to play a role in HCV infections. AMPK-activating
drugs inhibited the replication of HCV replicons concomitant with
a decrease in cellular lipid levels, while knock down of the
upstream activator LKB1 led to increased replication, [84],
consistent with our findings with RVFV, KUNV, SINV, and
VSV. Importantly, KUNV could be partially rescued from
AMPK-mediated restriction by the addition of the fatty acid
palmitate. Thus, AMPK may restrict multiple families of viruses
through this mechanism. Since all positive strand RNA viruses are
thought to induce membrane modifications for viral RNA
replication, and include a large number of medically significant
groups (e.g., Picornaviruses, and Coronaviruses) [16,80,85,86], it
will be important to determine the full scope of viruses restricted
by AMPK as well as the mechanism of restriction.
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interesting to speculate how AMPK could be activated in response
to these viral infections. We have found that both live virus and
UV-inactivated replication incompetent RVFV is capable of
activating AMPK via LKB1. This suggests that the energy sensing
pathway is responsible for this activation yet we were unable to
detect global changes in cellular energy levels during the period in
infection when AMPK becomes phosphorylated. Thus, we
hypothesize that RVFV infection induces a localized drop in
cellular energy to activate AMPK. Since this is independent of
viral replication and can restrict a large panel of disparate viruses
that have the commonality of entering cells via endocytic routes
and fusing within these compartments, we postulate that a local
energy drop may occur during these steps. Since endocytosis is a
highly energetic process usurped by many viruses, it is possible that
increased levels could themselves could provide the trigger for this
rapidly inducible antiviral response. We have previously reported
that receptor-mediated endocytosis, employed by many viruses
including KUNV, SINV and VSV for entry is intact in AMPK
deficient cells [40]. Therefore at least some routes of endocytic
entry used by viruses are unaffected by AMPK, and may provide a
trigger for activation rather than a point of restriction. This would
allow broad activation of AMPK by many types of viruses
internalized by such routes and provide a rapid response to restrict
virus infection by inhibiting fatty acid synthesis.
Since AMPK activators are currently in the clinic to treat
metabolic disorders such as type II diabetes [87], and restrict
RVFV and KUNV replication in cell culture, they may prove to
be useful antiviral therapeutics. Several AMPK activating drugs
have been shown to reduce morbidity and mortality during lethal
influenza infection in mice [88]. In addition, treatment of AMPK-
activating drugs inhibited infection of HCMV and HIV in cells,
and the addition of AMPK-activating drugs such as Metformin to
current HCV treatment regimens had promising, albeit modest,
effects on reducing patient viral loads [84,89–92]. Infections with
HCMV, HIV, and HCV have also been shown to inhibit AMPK
activity [56,84,89,92]. AMPK may have multiple effects on these
infections since different downstream mechanisms have been
implicated [56,84,89,92,93]; however, this suggests the possibility
that some viruses have developed mechanisms of immune evasion
that target AMPK. Taken together, AMPK plays a broad role in
cellular innate immunity through potent inhibition of fatty acid
synthesis, which is broadly utilized by viruses, suggesting that
AMPK and perhaps other modulators of lipid biosynthesis are
potential targets for broad pan-antiviral therapeutics.
Materials and Methods
Cells, Antibodies, Reagents, and Viruses
MEFs, BHK and U2OS cells were maintained at 37uCi n
DMEM supplemented with 10% FBS (Sigma), 100 mg/ml
penicillin/streptomycin, 2 mM L-glutamine, and 10 mM Hepes.
LKB1
2/2 MEFs [94] were complemented with MIGR (Vector) or
FLAG-LKB1-MIGR (LKB1 cDNA) retrovirus and sorted on
GFP+ cells by FACS as previously described [40]. Rift Valley fever
virus MP-12 was grown in Vero-E6 cells supplemented with 10%
FBS [51]. RVFV was UV-inactivated in a Stratalinker. KUNV
(gift from M. Diamond) was grown in BHK cells. VSV-GFP [95]
was grown in BHK cells as described [96]. SINV-GFP virus [97]
was grown in C636 cells [98]. All viruses were tittered by plaque
assay in BHK cells. Antibodies were obtained from the following
sources: anti-RVFV ID8 (gift from C. Schmaljohn USAMRIID),
anti-KUNV 9NS1 (gift from R. Doms), anti-tubulin (Sigma), and
anti-P-AMPK, t-AMPK, P-ACC, t-ACC, P-eEF2, t-eEF2 (Cell
Signaling Technology). Fluorescently labeled secondary antibodies
and BODIPY-TR were obtained from Invitrogen. HRP-conju-
gated antibodies were obtained from Amersham. A769662 was
obtained from Santa Cruz. Other chemicals were obtained from
Sigma.
Plaque Assay
Viruses were plaqued on MEFs as indicated. Confluent
monolayers were treated with serial dilutions of virus for two
hours, after which the viral inoculums were removed, and cells
were overlayed with 0.75% agarose in MEM, and incubated at
37uC for 48 hours. Cells were fixed in 10% formaldehyde, and
stained with crystal violet. Plaque number was determined
manually, and plaque diameter was measured using MetaXpress
software and used to calculate areas.
Viral Infections and Immunofluorescence
For all infections, washes and media changes were performed in
the control untreated wells, as well as those infected with virus.
Viral immunofluorescence experiments were performed in 96 well
plates as previously described [99]. Briefly, cells were grown
overnight in 96 wells plates, media was removed and fresh media
was added. When appropriate, drug was added at the indicated
concentration in 5 ml PBS, and cells were incubated at 37uC for
1 hour before addition of virus. Cells were infected with the
indicated MOI of virus in complete media and spinoculated for
1 hour at 1200 RPM, and incubated at 37uC. Cells were fixed and
processed for immunofluorescence as previously described
10 hours post infection for RVFV, SINV, and VSV, and 24 hours
post infection for KUNV unless otherwise indicated [100]. Briefly,
cells were fixed in 4% formaldehyde/PBS, washed twice in PBS/
0.1% TritonX-100 (PBST), and blocked in 2% BSA/PBST.
Primary antibodies were diluted in block, added to cells, and
incubated overnight at 4uC. RVFV was stained with anti-RVFV
ID8; KUNV was stained with anti-KUNV 9NS1. VSV and SINV
expressed GFP, and did not require antibody staining. Cells were
washed three times in PBST, and incubated in secondary antibody
with Hoescht33342 (Sigma) counterstain for one hour at room
temperature. Plates were imaged at 106 using an automated
microscope (ImageXpress Micro), capturing four images per well
per wavelength, and quantification was performed using MetaX-
press image analysis software. Significance was determined using a
Student’s T-test. For immunofluorescence assays, a minimum of
three wells per condition was imaged, with four images taken per
well. To control for variability in baseline level of infection, a
Student’s T-test was performed on both the raw percent infection
data in each individual experiment, and across a minimum of
three replicate experiments where the untreated control had been
normalized. Significance was determined if p,0.05 in all tests.
One Step Growth Curve
MEFs were infected with RVFV MOI 1 in 6 well dishes and
incubated at 37uC. Two hours post infection, inoculums was
removed, and fresh medium was added. At indicated time point,
medium was removed from infected cells and tittered on BHK
cells by plaque assay.
RVFV Binding Assay
MEFs were grown overnight in a 6 well dish. Medium was
replaced with 1 mL of fresh complete medium and cells were
chilled to 4uC for 10 minutes. RVFV (MOI 10) was added on ice,
and cells were incubated at 4uC for 1 hour to allow virus binding.
Cells were washed in PBS, then treated with either PBS or 0.25%
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were pelleted, then washed again, and lysed in Trizol to extract
total RNA. Samples were then prepared for quantitative RT-PCR.
cDNA was prepared from total RNA using M-MLV reverse
transcriptase (Invitrogen) random primers, and transcripts were
amplified by quantitative PCR. DDCT was calculated for RVFV S
segment using GAPDH as a cellular loading control.
Time of Addition Assay
Time of addition experiments were performed as previously
described [51]. U2OS cells were grown overnight, and the media
was replaced. Cells were infected with RVFV (MOI 1), spun at
1200 rpm for 1 hour, and subsequently incubated at 37uC.
12 mM 2DG, 200 mM A769662, or 12 mM Ammonium Chloride
were added either 1 hour prior to infection (21), with infection (0),
or 1, 2 or 4 hours after infection. 10 hours post infection cells were
fixed in 4% formaldehyde in PBS and processed for immunoflu-
orescence. Significance was determined using a Student’s T test.
Immunoblotting and Northern blotting
MEFs were infected with RVFV MOI 1 in 6 well dishes (,50%
infection) and incubated at 37uC for indicated time point. For protein
analysis, cellswere washed brieflyin cold PBS and lysed in NP40 lysis
buffer supplemented with protease (Boehringer) and phosphatase
(Sigma) inhibitor cocktails. Samples were separated by SDS-PAGE
and blotted as described [69]. HRP-conjugated secondary antibodies
and Western Lightening Chemiluminescence Reagent were used for
visualization. To analyze downstream effectors of AMPK, MEFs
were treated with 12 mM 2DG, 10 mM oligomycin, or 100 uM
A769662 for 4 hours, lysed and blotted as above.
For RNA analysis, cells were lysed in Trizol buffer, and RNA
was purified as previously described [100]. To detect viral mRNA,
total RNA from infected cells was separated on a 1% agarose/
formaldehyde gel and blotted with the indicated probes as
previously described [100]. Samples were quantified and normal-
ized against controls using ImageQuant software.
Cellular Lipid Staining
Cellular lipids were stained as previously described [82,84].
MEFs were grown to confluence overnight, and then treated with
PBS vehicle or 100 mM A769662 for 10 hours. Cells were fixed in
4% formaldehyde for 10 minutes and washed three times in PBS.
Staining was performed with 10 mg/ml BODIPY-TR and
counterstained with Hoescht33342 in 100 mM glycine in PBS
overnight. Cells were washed three times in PBS and imaged using
the ImageXpress Micro automated microscope. Integrated
intensity of BODIPY signal per cell area was calculated using
MetaXpress image analysis software. Significance was determined
using a Student’s T test.
Fatty Acid Synthesis Bypass Assay
Exogenous palmitate addition was performed as previously
described [102]. Delipidated Fetal Calf Serum and Albumin-
bound palmitate were prepared as described [102] and obtained as
a kind gift from Robert Rawson. U2OS cells were set up on day 0
in 96 well plates and grown over night in normal growth medium.
On day 1 medium was removed and cells were washed briefly in
PBS. Cells were treated with low glucose DMEM supplemented
with 5% delipidated Fetal Calf Serum with or without 100 mM
Albumin-bound palmitate, and incubated overnight. On day 2
cells were treated with 100 mM A769662 or PBS vehicle for
1 hour, and infected with RVFV for 10 hours. Cells were fixed,
processed for immunofluorescence, and imaged at 106using the
automated microscope ImageXpress Micro, as described above.
Quantification was performed using MetaXpress image analysis
software. Significance was determined using a Student’s T-test.
Supporting Information
Figure S1 AMPK restricts RVFV. A. Time course of RVFV
infection in WT and AMPKa1/AMPKa2
2/2 MEFs. Cells were
infected with RVFV and fixed at indicated time post infection.
(RVFV, green; nuclei, blue) B. Quantification of A. A represen-
tative of triplicate experiments is shown.
(TIF)
Figure S2 AMPK inhibition leads to increased RVFV infection.
A. U2OS cells were pretreated with 10 mM Compound C or PBS
(untreated) for 1 hour and infected with serial dilutions of RVFV
for 10 hours and processed for immunofluorescence. Data are
displayed as the average percent infection relative to untreated
control 6 SD from triplicate experiments. * indicates p,0.05. B.
Cellular Toxicity in response to drug treatment. U2OS were
pretreated with 10 mM 2DG, 10 mM oligomycin, 100 mM
A769662, 10 mM Compound C, 10 mg/ml STO609 or PBS
(untreated) for 1 hour, infected with RVFV, and processed for
immunofluorescence 10 hpi. Cell nuclei were counted using
automated microscopy as a measure of cytotoxicity. Data are
displayed as the average number of nuclei relative the untreated
control 6 SD from triplicate experiments.
(TIF)
Figure S3 Dose-dependent inhibition of RVFV infection..
U2OS cells were pretreated with serial dilutions of A769662 (A),
2DG (B), or STO609 (C) prior to infection with RVFV (MOI 1),
and processed for immunofluorescence 10 hpi. Data are displayed
as the average percent infection relative to the 0 drug control 6
SD from triplicate experiments. * indicates p,0.05.
(TIF)
Figure S4 A769662 activates AMPK to restrict infection. A. WT
and AMPKa1/AMPKa2
2/2 MEFs were pretreated with 100 mM
A769662 or PBS (untreated) for 1 hour, then infected with RVFV
(MOI 1) for 10 hours and processed for immunofluorescence. Data
are displayed as the average percent infection relative to the WT
untreated control 6 SD from triplicate experiments. * indicates
p,0.05.B.Cell numbersfrom (A) asameasure ofcelltoxicity.Data
are displayed as the average number of nuclei relative to the
untreated 6 SD from triplicate experiments.
(TIF)
Figure S5 Cellular ATP content is unchanged during RVFV
infection. WT MEFs were treated with 2DG (12 mM), A769662
(mM), or infected with RVFV at MOI 2.5 or 12, spun at 1200 rpm
for 1 hour, and incubated for 4 hours. ATP concentration was
measured by luminescence. Data are displayed as average RLU
relative to untreated control 6SD from triplicate experiments. *
indicates p,0.05.
(TIF)
Figure S6 AMPK’s role in the type I interferon response. A–B.
WT and AMPKa1/AMPKa2
2/2 MEFs were infected with
RVFV for 10 hours. Expression of IFNb (A) and OAS1 (B) were
measured by qRT-PCR. Data are representatives of duplicate
experiments. C. WT MEFs were treated with IFNb for
15 minutes or 4 hours, lysed, and assayed by immunoblot for
phospho-AMPK and phospho-ACC. Total AMPK and tubulin
were assayed. A representative of triplicate experiments is shown.
D. Quantification of C. using Image J software.
(TIF)
AMPK Restricts Rift Valley Fever Virus
PLoS Pathogens | www.plospathogens.org 12 April 2012 | Volume 8 | Issue 4 | e1002661Figure S7 Quantification of Immunoblots using Image J
software. A–D. Phosphorylation of AMPK and downstream
effectors upon RVFV infection. WT MEFs were infected with
RVFV (MOI 1) for 4 or 8 hours. Lysates were collected, assayed
by immunoblot and quantified for phospho-AMPK (A), phospho-
ACC2 (B), phospho-ACC1 (C), and phospho-eEF2 (D) normal-
izing to the tubulin loading control. Data are displayed as the
average density relative to untreated at 4 hours from triplicate
experiments. E–H. Phosphorylation of AMPK and downstream
effectors in WT and AMPKa1/AMPKa2
2/2 MEFs. Cells were
treated with AMPK activators 2DG (12 mM), oligomycin (OM,
10 mM), and A769662 (100 mM) for 4 hours. Lysates were
collected, assayed by immunoblot, and quantified as above for
phospho-AMPK (E), phospho-ACC2 (F), phospho-ACC1 (G), and
phospho-eEF2 (H) normalized to the tubulin loading control. Data
are displayed as the average density relative to untreated at
4 hours from triplicate experiments.
(TIF)
Figure S8 UV-inactivated RVFV is replication incompetent.
U2OS cells were infected with live (MOI 1) and UV-inactivated
virus (equivalent volume to MOI 1) for 10 hours, and processed
for immunofluorescence. (RVFV-N, green; nuclei, blue)
(TIF)
Figure S9 AMPK is not activated by RVFV in LKB1 null
MEFs.LKB12/2;LKB1 and LKB12/2;Vec MEFs were infected
with RVFV (MOI 1) for 4 hours. Lysates were collected and assayed
byimmunoblot forphospho-AMPK.Total AMPKand tubulin were
assayed. Representative blot of duplicate experiments is shown.
(TIF)
Figure S10 A: mTORC1 is not required for AMPK-mediated
restriction of RVFV. WT and AMPKa1/AMPKa2
2/2 MEFs
were pretreated with 10 nM Rapamycin or PBS for 1 hour and
infected with RVFV (MOI 1) for 10 hours and processed for
immunofluorescence. A representative of duplicate experiments is
shown. B. Autophagy does not restrict RVFV. RVFV was
plaqued in MEFs expressing a control hairpin RNA or a hairpin
against Atg5. C. Atg5 mRNA expression by qRT-PCR in MEFs
expressing a control hairpin RNA or a hairpin against Atg5
normalized to GAPDH.
(TIF)
Figure S11 Palmitate treatment does not inhibit AMPK
activation or signaling. U2OS cells were treated with palmitate
overnight, then treated with 2DG (12 mM) and A769662
(100 mM) for 10 hours. Lysates were collected and assayed by
immunoblot for phospho-AMPK, and phospho-ACC. Total
AMPK, ACC and tubulin were assayed. Representative blot of
duplicate experiments is shown.
(TIF)
Figure S12 Addition of palmitate partially restores KUNV
infection in the presence of A769662. A. U2OS cells were
pretreated with 100 mM palmitate and 100 mM A769662 or PBS
1 hour prior to infection with KUNV (MOI 1). Cells were
incubated for 16 hours, and processed for immunofluorescence.
(KUNV-Ns1, green; nuclei, blue) B. Quantification of A. Data are
displayed as the normalized percent infection relative to the non-
A769662 treated control 6SD in triplicate experiments; *
indicates p,0.05. C. Quantification of non-drug treated samples
in (A). Palmitate treatment inhibited KUNV infection. Data are
displayed as the normalized percent infection relative to the
untreated vehicle control 6SD in triplicate experiments; *
indicates p,0.05.
(TIF)
Text S1 The supporting information contains the methods used
in Figures S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12.
(PDF)
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